Literature DB >> 28414990

Medical outcomes associated with prescription opioid abuse via oral and non-oral routes of administration.

Jody L Green1, Becki Bucher Bartelson2, M Claire Le Lait3, Carl L Roland4, Elizabeth T Masters5, Jack Mardekian6, J Elise Bailey7, Richard C Dart8.   

Abstract

BACKGROUND: Prescription opioid abuse and misuse is a serious and growing public health issue. While the most common form of abuse is swallowing intact tablets/capsules, some abusers manipulate, or tamper with, these medications by altering the dosage form to allow for non-oral routes of administration (e.g., injection, inhalation) in order to achieve more rapid or enhanced psychoactive effects. Because administration of opioids via non-oral routes results in greater systemic availability and more rapid central nervous system penetration, we hypothesized that death and major medical outcomes occur more frequently with non-oral routes compared to oral route alone.
METHODS: This retrospective cohort study analyzed data from the Researched Abuse, Diversion and Addiction-Related Surveillance (RADARS) System Poison Center Program to investigate relative risk of prescription opioid abuse via oral and non-oral routes.
RESULTS: While the oral route was the most commonly reported route of abuse (64.0%), non-oral routes were reported in 14.6% exposures and unknown routes in 21.4% exposures. The relative risk of an exposure resulting in death or major effect was 2.43 (95% CI 1.97, 2.99) if non-oral routes were reported compared to exposures involving oral route only.
CONCLUSION: Analysis of acute health events recorded by poison centers indicates that death or major effects are twice as likely to occur with intentional abuse of prescription opioids via non-oral routes of administration than ingestion alone. Effective interventions to prevent abuse via non-oral routes of solid dosage forms of prescription opioids, such as abuse-deterrent formulations could have a significant public health impact.
Copyright © 2017 The Authors. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Abuse- deterrent; Medical outcomes; Opioid abuse; Prescription drug abuse; Route of abuse

Mesh:

Substances:

Year:  2017        PMID: 28414990     DOI: 10.1016/j.drugalcdep.2017.01.039

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


  11 in total

1.  The effect of concurrent access to alcohol and oxycodone on self-administration and reinstatement in rats.

Authors:  Kristen N Amico; Miranda E Arnold; Morgan S Dourron; Matthew G Solomon; Jesse R Schank
Journal:  Psychopharmacology (Berl)       Date:  2022-08-16       Impact factor: 4.415

2.  Comparative Rates of Mortality and Serious Adverse Effects Among Commonly Prescribed Opioid Analgesics.

Authors:  David L Murphy; Jacob A Lebin; Stevan G Severtson; Heather A Olsen; Nabarun Dasgupta; Richard C Dart
Journal:  Drug Saf       Date:  2018-08       Impact factor: 5.606

Review 3.  Managing severe pain and abuse potential: the potential impact of a new abuse-deterrent formulation oxycodone/naltrexone extended-release product.

Authors:  Joseph V Pergolizzi; Robert Taylor; Jo Ann LeQuang; Robert B Raffa
Journal:  J Pain Res       Date:  2018-02-08       Impact factor: 3.133

Review 4.  An overview of abuse-deterrent opioids and recommendations for practical patient care.

Authors:  Jeremy A Adler; Theresa Mallick-Searle
Journal:  J Multidiscip Healthc       Date:  2018-07-11

5.  Pharmacokinetics and Abuse Potential of Benzhydrocodone, a Novel Prodrug of Hydrocodone, After Intranasal Administration in Recreational Drug Users.

Authors:  Travis C Mickle; Sven M Guenther; Andrew C Barrett; Kathryn Ann Roupe; Jing Zhou; Daniel Dickerson; Lynn R Webster
Journal:  Pain Med       Date:  2018-12-01       Impact factor: 3.750

6.  Evaluation of Abuse and Route of Administration of Extended-Release Tapentadol Among Treatment-Seeking Individuals, as Captured by the Addiction Severity Index-Multimedia Version (ASI-MV).

Authors:  Suzanne K Vosburg; Jared Beaumont; S Taryn Dailey-Govoni; Stephen F Butler; Jody L Green
Journal:  Pain Med       Date:  2020-09-01       Impact factor: 3.750

7.  Examining associations between prescription stimulant misuse frequency and misuse characteristics by race/ethnicity.

Authors:  Jocelyne Mendez; Kyle Yomogida; Wilma Figueroa; Kate Diaz Roldan; Niloofar Bavarian
Journal:  J Ethn Subst Abuse       Date:  2021-08-06       Impact factor: 1.507

8.  Nonmedical Use of Xtampza® ER and Other Oxycodone Medications in Adults Evaluated for Substance Abuse Treatment: Real-World Data from the Addiction Severity Index-Multimedia Version (ASI-MV®).

Authors:  Jody L Green; Rebekkah S Robbins; Taryn Dailey-Govoni; Stephen F Butler
Journal:  J Pain Res       Date:  2021-06-15       Impact factor: 3.133

Review 9.  Mitigation of IV Abuse Through the Use of Abuse-Deterrent Opioid Formulations: An Overview of Current Technologies.

Authors:  Richard L Rauck
Journal:  Pain Pract       Date:  2019-02-28       Impact factor: 3.183

10.  Postmarketing Analysis of Misuse, Abuse, and Diversion of Xtampza ER.

Authors:  Stevan Geoffrey Severtson; Scott E D Kreider; Elise C Amioka; Zachary R Margolin; Janetta L Iwanicki; Richard C Dart
Journal:  Pain Med       Date:  2020-12-25       Impact factor: 3.750

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.